NCT07817225Active, not recruiting
Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation
Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation: a Retrospective Study
Source: ClinicalTrials.gov · Last updated 16 Sept 2026
Brief summary (registry, in English)
Non-functioning pancreatic neuroendocrine tumors (NF-PanNETs) are heterogeneous neoplasms of the pancreatic endocrine tissue, displaying variable clinical behavior from indolent to highly aggressive forms. Their often asymptomatic nature and lack of reliable preoperative biomarkers make clinical management particularly challenging. This exploratory study will investigate cell-free DNA (cfDNA) as a potential non-invasive biomarker in NF-PanNETs. cfDNA samples from approximately 30 patients, representing distinct clinical courses (active surveillance, indolent post-surgical, and aggressive post-surgical cases), will be analyzed using advanced methylome and nucleosome footprinting techniques. The aim is to evaluate cfDNA's diagnostic and prognostic potential to improve disease monitoring and support personalized therapeutic strategies in NF-PanNET patients.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 30 (actual)
- First submitted
- 8 Sept 2026
- Start date
- 12 Sept 2026
- Primary completion date
- 12 Sept 2027
- Lead sponsor
- Massimo Falconi
- Diseases
- Neuroendocrine tumours, Pancreatic cancer
- NCT number
- NCT07817225
What you commit to
- Study type: Observational
- Participants enrolled: 30
- From 12 Sept 2026 to the primary completion date, 12 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Genetic syndromes associated with NF-PanNETs (e.g., MEN1, VHL).
Other
- Functioning PanNETs.
- Inadequate quality or quantity of circulating-free DNA (cfDNA) extracted from plasma samples.
Who the study is looking for
- Age ≥18 years.
- Diagnosis of sporadic, well-differentiated, non-functioning pancreatic neuroendocrine tumor (NF-PanNET).
- Signed informed consent for the use of plasma samples stored in the "NETbank" biobank.
- Availability of pre-operative or surveillance plasma samples.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS San Raffaele Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.